- Tytuł:
- Serum levels of anti-corona virus specific-IgG and -IgM antibodies in COVID-19 patients at admission and at discharge
- Autorzy:
- Olatunbosun Arinola, Ganiyu
- Powiązania:
- https://bibliotekanauki.pl/articles/2040148.pdf
- Data publikacji:
- 2021-03-30
- Wydawca:
- Uniwersytet Rzeszowski. Wydawnictwo Uniwersytetu Rzeszowskiego
- Tematy:
-
anti-SARS-CoV-2 specific antibodies convalescence plasma
COVID-19
spike protein
vaccine - Opis:
- Introduction. Clear understanding of duration of antibody based protective immunity following natural infection with SARSCoV-2 will give idea about the efficacy of proposed prophylactic vaccines against SARS-CoV-2, establishment of herd immunity and use of convalescent plasma. Aim. This study clarified the kinetics and magnitude of the initial antibody response against SARS-CoV-2 in a cohort of symptomatic COVID-19 patients from Ibadan, Nigeria. Material and methods. This study quantified immunoglobulin M (IgM) and G (IgG) antibodies recognizing the SARS-CoV-2 Spike (S) protein in 35 symptomatic COVID-19 patients at admission and at discharge using ELISA. Results. CovIgG was positive in none (0)% and 20% of COVID-19 patients at admission and at discharge respectively while CovIgM was positive in 54% and 69% of COVID-19 patients at admission and at discharged respectively. The level of CovIgG was significantly higher in COVID-19 patients at discharge compared with the level at admission while the level of CovIgM was insignificantly reduced in COVID-19 patients at discharge compared with the level at admission. Conclusion. The data indicates increased anti-SARS-COV-2 IgG Spike antibody in symptomatic COVID-19 at discharge, thus providing basis for antibody-based therapies to treat COVID-19 patients
- Źródło:
-
European Journal of Clinical and Experimental Medicine; 2021, 1; 5-9
2544-2406
2544-1361 - Pojawia się w:
- European Journal of Clinical and Experimental Medicine
- Dostawca treści:
- Biblioteka Nauki